
Pennsylvania House makes last-ditch effort to stave off cuts at Philadelphia's public transit agency
The bill — which includes funding for highways, too — increases aid for transit agency operations by $292 million, or about 25% more, with the lion's share of the money going to the Philadelphia-based Southeastern Pennsylvania Transportation Authority.
SEPTA has said it cannot keep waiting for more aid and must start making cuts in the coming days, which it says will be more drastic than any undertaken by a major transit agency in the United States.
The nation's sixth-largest public transit system has warned that it will cut half its services by Jan. 1 and be unable to provide enhanced service for major tourist events next year. Those include FIFA World Cup matches in Philadelphia, events surrounding the celebration of the nation's 250th birthday, Major League Baseball's all-star game, the PGA Championship and NCAA March Madness games.
The legislation passed in the House by 108-95 over the objection of nearly every Republican in the chamber. It has the support of Democratic Gov. Josh Shapiro, but Republican senators have resisted increasing aid for transit.
The deadline push comes after two years of stalemate, and as transit agencies nationwide struggle with rising costs and lagging ridership.
SEPTA has said that on Thursday it will begin a 10-day preparation period for 20% across-the-board service cuts. Those take effect Aug. 24 and include eliminating bus routes with lower ridership and reducing the frequency of bus, trolley and rail services across the region.
Under the plan, fares will then rise by 21.5% on Sept. 1 for the system's approximately 800,000 daily riders. A weekday ride would rise from $2.50 to $2.90 on a bus, train or trolley, it said.
Soon after, the agency would impose a hiring freeze and carry out additional service cuts by Jan. 1 that will mean it will have eliminated half its current services, it has said. That will include cutting more regional rail and bus routes and imposing a 9 p.m. curfew on rail services, some of which go as late as 1:30 a.m. currently.
Democrats say shoring up public transit agencies around the state is critical to the economy and making sure people can get to work, school and medical appointments.
Republicans have objected that transit agencies need to become more efficient, highways need more state funding and transit riders should pay higher fares.
Transit agencies in Pittsburgh and elsewhere around Pennsylvania also say they are making cuts or raising fares, or both.
Under the bill, an extra 1.75 percentage points of state sales tax revenue — from 4.4% to 6.15% — would go toward a public transit fund to help pay for the operations of several dozen transit systems around the state. The increase represents about $292 million.
Democrats inserted several other provisions into the bill in a bid to pick up Republican votes.
That includes funding up to $325 million in borrowing authority for highway projects, allocating $275 million for improvements to smaller, rural roads and commissioning the creation of performance standards for the Philadelphia and Pittsburgh transit agencies.
___
Follow Marc Levy on X at https://x.com/timelywriter.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
4 minutes ago
- Time of India
Qualcomm localising module production in India, supporting partners' manufacturing plans
US-based chip major Qualcomm is localising automotive module production in India and is supporting its top-tier ecosystem partners in their plan to move manufacturing into the country, a senior company official has said. Qualcomm Technologies, group general manager for automotive, industrial and embedded IoT, Nakul Duggal, told PTI that the company is investing heavily in India to support local automotive companies. "We build a lot of modules. Those modules are typically built in Taiwan, or China, or Korea, but we are now actively working in India to localise this. We, of course, partner with our Tier 1 ecosystem, such that as they move their manufacturing to India, we have been supporting them," he said. Duggal said that Qualcomm is a fabless company, which means it designs the chips but doesn't manufacture them. "For us, it's really about being able to create opportunities in our supply chain to be able to direct that (manufacture)," he said. Qualcomm has approximately 22,000 employees, or 60 per cent of its workforce, in India. Duggal said that the company has a local team to support domestic car manufacturers. Qualcomm has been bullish on chipsets for automobiles , especially electric vehicles . The company has partnered with all the major car OEMs (original equipment manufacturers), including Tata Motors, Mahindra, Maruti Suzuki and Hyundai, to provide them with chipsets for modernising cars. It has the Snapdragon Elite chipset platform for telematics, infotainment and driver assistance, including ADAS (Advanced Driver Assistance Systems). Duggal said that in 2026, there will probably be a dozen vehicles that will deploy its Snapdragon Cockpit Elite and Snapdragon Ride Elite SoC (System on Chip), which were announced in October 2024 and delivered to customers in early 2025. He said that India has a substantial domestic footprint encompassing both domestic and global automakers that manufacture locally. "There is a huge need for building products that cater to the needs of the Indian region. Rather than bringing in a product that is built for a global customer, build a product for a local customer. That necessitates for an OEM the need to have engineering capability, creative capability, to actually think about the needs of the local region, and we are starting to see that happen," he said. Duggal said building an automotive product for the local market will generate a competitive advantage, and China has benefited from this trend. The automotive segment of the company accounts for around 10 per cent of its global revenue, which is around USD 3.6 billion to USD 3.8 billion. The company has set a target to double the total revenue from the automotive business to about USD 8 billion by 2029.
&w=3840&q=100)

Business Standard
4 minutes ago
- Business Standard
Alkem Labs Q1 profit rises 22% to ₹664 cr on India, overseas sales growth
Alkem Laboratories on Tuesday reported a 22 per cent year-on-year (Y-o-Y) rise in its consolidated net profit for the June quarter (Q1FY26) to ₹664.3 crore, up from ₹545.2 crore in the same period last year. Revenue from operations increased 11.2 per cent Y-o-Y to ₹3,371 crore in Q1FY26 from ₹3,031 crore in Q1FY25. The company attributed this growth to strong sales in both India and international markets. Commenting on the performance, Vikas Gupta, Chief Executive Officer of Alkem, said Q1FY26 marked a strong start to the year, with healthy growth across both domestic and overseas markets. India sales grew 12 per cent Y-o-Y to ₹2,265 crore in the June quarter, while international sales rose 8.9 per cent to ₹1,054 crore, contributing 31.7 per cent to overall revenue. In the international business, the United States market recorded sales of ₹698 crore, up 8.8 per cent from ₹641.6 crore a year earlier, contributing 21 per cent to total sales. Sales from other international markets — including Latin America, Australia, and Europe — rose 9.1 per cent to ₹355.6 crore, contributing 10.7 per cent to revenue. Gupta said the company is strategically accelerating its focus on the non-US business segment by strengthening its presence in high-potential markets and capturing new opportunities aligned with Alkem's long-term growth ambitions. Alkem also announced it will incorporate a Saudi Arabia-based subsidiary, holding a 51 per cent stake. 'The subsidiary is proposed to be incorporated as a limited liability company and will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products within the Kingdom of Saudi Arabia,' the company said in a filing to the exchanges. On Tuesday, Alkem Laboratories' share price rose 6.7 per cent to close at ₹5,167 on the Bombay Stock Exchange (BSE).
&w=3840&q=100)

Business Standard
4 minutes ago
- Business Standard
Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz
Ahmedabad-based Zydus Lifesciences on Tuesday reported a 5.9 per cent year-on-year (Y-o-Y) increase in consolidated net profit for the June quarter (Q1FY26) to ₹1,466 crore, up from ₹1,419 crore in the same quarter last year. Revenue from operations rose 3.3 per cent Y-o-Y to ₹6,573 crore in Q1FY26 from ₹6,207 crore in Q1FY25. The growth was driven by strong performances in the company's domestic and international formulations segments, even as its consumer wellness and US businesses saw muted growth. In Q1FY26, the India formulations business grew 5.8 per cent Y-o-Y to ₹2,374 crore, with the company stating that its branded formulations segment outperformed the market in both chronic and acute categories. The international markets formulations business posted a 36.8 per cent Y-o-Y increase to ₹726.5 crore, while the active pharmaceutical ingredients (API) segment rose 11.3 per cent to ₹157.5 crore. 'All-round growth across key geographies was driven by strong demand and focused execution,' Zydus said in a filing to the exchanges. The US market, which contributes 49 per cent of consolidated revenue, saw only a 2.9 per cent Y-o-Y increase to ₹3,181 crore, despite the launch of three new products during the quarter. The consumer wellness business, contributing 13 per cent to consolidated revenue, grew 2 per cent Y-o-Y to ₹854.9 crore, with performance impacted by seasonal brands. However, the company said its core wellness brands posted strong double-digit growth, reflecting the underlying strength of its portfolio and balanced business model. Commenting on the results, Sharvil Patel, Managing Director of Zydus Lifesciences, said the Q1 performance reflected disciplined execution, with most key businesses meeting expectations. 'We remain firmly on track to achieve our FY26 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth,' Patel added. On Tuesday, Zydus Lifesciences shares closed flat with a 0.05 per cent rise at ₹956 apiece on the Bombay Stock Exchange (BSE).